Elite 50% OFF Act now – get top investing tools Register Now!

MiNK Therapeutics

Contributing Author

Recent Articles by MiNK Therapeutics

Nov-20	MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors INKT GlobeNewswire
Nov-14	MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation INKT GlobeNewswire
Nov-07	MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 INKT GlobeNewswire
Nov-05	MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development INKT GlobeNewswire
Oct-30	MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting INKT GlobeNewswire
Sep-29	MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors INKT GlobeNewswire
Sep-25	MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA INKT GlobeNewswire
Sep-18	MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development INKT GlobeNewswire
Aug-14	MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results INKT GlobeNewswire
Jul-31	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report INKT GlobeNewswire
Jul-15	MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy INKT GlobeNewswire
Jul-11	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer INKT GlobeNewswire
Jun-10	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting INKT GlobeNewswire
Jun-02	MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients INKT GlobeNewswire
May-15	MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress INKT GlobeNewswire
May-05	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report INKT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.